Venture Capital · Profile from Venture Capital Research Companion
Venrock
The Rockefeller family's venture arm, formalised in 1969, which backed Intel and Apple in its first decade, built one of the longest-running combined technology-and-healthcare venture franchises, added a public/crossover healthcare business (Venrock Healthcare Capital Partners), and today operates as an independent, mid-sized, multi-sector partnership whose brand rests more on longevity and breadth than on any single fund-defining outlier.
At a glance
- Founded
- 1969, New York (Rockefeller Center); roots in Laurance S. Rockefeller's personal venture investing from the late 1930s
- Founders
- Laurance S. Rockefeller and members of the Rockefeller family; early professional leadership included Peter Crisp (long-time managing partner)
- Headquarters
- Palo Alto, California; offices in New York and (historically) Cambridge/Boston
- Ownership / structure
- Private partnership (Venrock Management, LLC); originally capitalised by the Rockefeller family and family-associated institutions (MoMA, Rockefeller University, Memorial Sloan-Kettering); later opened to outside institutional LPs (e.g., the Wellcome Trust is a named LP)
- Leadership (2026)
- Flat partnership without a single public "managing partner" figurehead; long-tenured partners include Bryan Roberts (healthcare) and partners such as Bob Kocher, Nick Beim, Brian Ascher and Racquel Bracken (verify current roster); Venrock Healthcare Capital Partners led by Bong Koh and Nimish Shah (verify)
- AUM / capital raised
- ~$2.2bn total AUM reported in 2010; since then ~$2bn of reported venture-fund closes (Venrock VII–10) plus ~$2bn+ of healthcare crossover/public funds (VHCP series), implying ~$4.5bn+ of commitments raised since 2009 (sum of reported closes; firm does not publish a single AUM figure)
- Stage focus
- Early stage (seed to Series B) in technology and healthcare; VHCP invests in late-stage private and small-cap public healthcare companies
- Signature investments
- Intel, Apple, 3Com, Gilead Sciences, Centocor, Genetics Institute, IDEC Pharmaceuticals, Millennium Pharmaceuticals, Check Point Software, DoubleClick, athenahealth, Castlight Health, Cloudflare, Dollar Shave Club, AppNexus, Shape Security, Dapper Labs; instructive outcomes: Castlight Health (post-IPO collapse), Dapper Labs (2021 peak, sharp reset), Nanosys (long-dated nanotech bet)
9 deals and moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1969
Intel
Early Venture Financing
1978
Apple
Venture Round
1987
Gilead Sciences
Early Venture
1995
Check Point Software
Venture Round
1999
athenahealth
Early Venture
2008
Castlight Health
Series A / Incubation
2009
Cloudflare
Series A
2012
Dollar Shave Club
Seed / Series A
2018
Dapper Labs
Series A